All In MedTech

FDA Clearance Tracker · P170043-S014

iStent Trabecular Micro-Bypass Stent System, iStent inject Trabecular Micro-Bypass System, iStent inject W Trabecular Mi

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 29, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 29, 2022

Approved

Time to decision

90 days

Received May 31, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P170043-S014
Device name
iStent Trabecular Micro-Bypass Stent System, iStent inject Trabecular Micro-Bypass System, iStent inject W Trabecular Mi
Applicant location
San Clemente, CA
Received
May 31, 2022
Decided
Aug 29, 2022
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P170043

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code OGO

FDA's approval statement

As written in FDA's record.

Approval for an alternate supplier and modifications to the specifications and incoming receiving testing for the stearalkonium heparin coating raw material.

Source documents

Other decisions for Glaukos Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.